Rapid downregulation of innate immune cells, interleukin-12 and interleukin-23 in generalized pustular psoriasis with infliximab in combination with acitretin

Dermatology

Volumn 225, Issue 4, 2013, Pages 338-343

  Tang, Min Moon ^a   Spanou, Z ^a   Tang, H ^a   Schibler, F ^a   Pelivani, N ^a   Yawalkar, N ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Acitretin; Generalized pustular psoriasis; Infliximab; Tumor necrosis factor

Indexed keywords

ACETYLSALICYLIC ACID; ALKALINE PHOSPHATASE; AMLODIPINE; ATORVASTATIN; BIOTIN; CANDESARTAN; CASPASE 3; CD163 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; ETRETIN; GLYCOPROTEIN P 15095; HEMOGLOBIN; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 8; STREPTAVIDIN; TUMOR NECROSIS FACTOR ALPHA;

AGED; APOPTOSIS; BONE MARROW CELL; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC KIDNEY FAILURE; DOWN REGULATION; GENERALIZED PUSTULAR PSORIASIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMAGE ANALYSIS; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; LEUKOCYTOSIS; MACROPHAGE; MALE; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PUNCH BIOPSY; PUSTULAR PSORIASIS; QUANTITATIVE ANALYSIS; REVIEW; SKIN BIOPSY;

ACITRETIN; AGED; ANTIBODIES, MONOCLONAL; DOWN-REGULATION; DRUG THERAPY, COMBINATION; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; MALE; PSORIASIS; TREATMENT OUTCOME;

EID: 84875216869     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000346243     Document Type: Review

References (27)

1. Borges-Costa J, Silva R, Gonçalves L, Filipe P, Soares de Almeida L, Marques Gomes M: Clinical and laboratory features in acute generalized pustular psoriasis: a retrospective study of 34 patients. Am J Clin Dermatol 2011; 12: 271-276.
2. Elewski BE: Infliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol 2002; 47: 796-797.
3. Schmick K, Grabbe J: Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab). Br J Dermatol 2004; 150: 367.
4. Trent JT, Kerdel FA: Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases. Dermatol Nurs 2005; 17: 97- 107.
5. Chandran NS, Chong WS: A dramatic response to a single dose of infliximab as rescue therapy in acute generalized pustular psoriasis of von Zumbusch associated with a neutrophilic cholangitis. Australas J Dermatol 2010; 51: 29-31.
6. Hassan AS, Kaelin U, Braathen LR, Yawalkar N: Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab. J Am Acad Dermatol 2007; 56: 217-221.
7. Schlapbach C, Ochsenbein A, Kaelin U, Hassan AS, Hunger RE, Yawalkar N: High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma. J Am Acad Dermatol 2010; 62: 995-1004.
8. Lowes MA, Chamian F, Abello MV, et al: Increase in TNF- - and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti- CD11a). Proc Natl Acad Sci USA 2005; 102: 19057-19062.
9. Benoit S, Toksoy A, Brocker EB, Gillitzer R, Goebeler M: Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol 2004; 150: 1009-1012.
10. Yawalkar N, Tscharner GG, Hunger RE, Hassan AS: Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J Dermatol Sci 2009; 54: 99-105.
11. Gottlieb AB, Masud S, Ramamurthi R, et al: Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor- - monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2008; 48: 68-75.
12. Marrakchi S, Guigue P, Renshaw BR, et al: Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365: 620-628.
13. Torti DC, Feldman SR: Interleukin-12, interleukin- 23, and psoriasis: current prospects. J Am Acad Dermatol 2007; 57: 1059-1068.
14. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al: Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128: 1207-1211.
15. Daudén E, Santiago-et-Sánchez-Mateos D, Sotomayor-López E, García-Díez A: Ustekinumab: effective in a patient with severe recalcitrant generalized pustular psoriasis. Br J Dermatol 2010; 163: 1346-1347.
16. Yawalkar N, Hunger RE: Successful Treatment of recalcitrant palmoplantar pustular psoriasis with sequential use of infliximab and adalimumab. Dermatology 2009; 218: 79-83.
17. Nestle FO, Conrad C, Tun-Kyi A, et al: Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135-143.
18. Santini M, Lapenta C, Logozzi M, et al: Type I interferon as a powerful adjuvant for monocyte- derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000; 191: 1777-1788.
19. Paquette L, Hsu NC, Kiertscher SM, et al: Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol 1998; 64: 358-367.
20. Laskin DL: Macrophages and inflammatory mediators in chemical toxicity: a battle of forces. Chem Res Toxicol 2009; 22: 1376- 1385.
21. Werner B, Bresch M, Brenner FM, Lima HC: Comparative study of histopathological and immunohistochemical findings in skin biopsies from patients with psoriasis before and after treatment with acitretin. J Cutan Pathol 2008; 35: 302-310.
22. Gordon KB, Bonish BK, Patel T, Leonardi CL, Nickoloff BJ: The tumour necrosis factor- alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 2005; 153: 945-953.
23. Bedini C, Nasorri F, Girolomoni G, Pità O, Cavani A: Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function. Br J Dermatol 2007; 157: 249-258.
24. Malaviya R, Sun Y, Tan JK, et al: Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J Am Acad Dermatol 2006; 55: 590-597.
25. Goedkoop AY, Kraan MC, Teunissen MB, et al: Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004; 63: 769-773.
26. Marble DJ, Gordon KB, Nickoloff BJ: Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci 2007; 48: 87-101.
27. Caproni M, Antiga E, Melani L, Volpi W, Del Bianco E, Fabbri P: Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized- controlled trial. J Clin Immunol 2009; 29: 210-214.